Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial.
Condition or disease
This is a long term open label study of AT1001 in patients with Fabry disease previously enrolled in a Phase 2 AT1001 trial. Patients will return to the study center approximately every 3 months for safety evaluations including physical exam, blood and urine tests.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 65 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Must have completed another Phase 2 trial of AT1001 in Fabry Disease
Women of childbearing potential must have negative pregnancy result
Male and Female subjects agree to use reliable method of contraception during treatment and four weeks after treatment has completed.
Subject is willing and able to provide written informed consent
Subject did not complete Phase 2 trial of AT1001 in Fabry Disease
Has undergone or is scheduled to undergo kidney transplantation or is currently on dialysis
Has been treated with another investigational drug (except AT1001) within 30 days of study start